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PROJECT BIOSHIELD, MORE THAN MEETS THE EYE:  A CRITIQUE OF 
THE U.S.’S PROPOSED SILVER BULLET FOR RESPONDING TO BIO-
TERRORISM   
By: Jodi A. Phillipo J.D.
“Project BioShield, the President declared, is ‘a part of a broader strategy to defend 
the United States against the threat of weapons of mass destruction.’”1
 In the last few years, Americans, through much pain and suffering, have come to 
realize that they are not invincible to an attack on U.S. soil.  In particular, the fear that 
there is no safe escape from the danger that a terrorist group may use new diseases or 
chemicals in future attacks, which could facilitate the spread of infection among the 
people of the Untied States.2 The fact that the mass population is not properly vaccinated 
to protect itself against the introduction of diseases (e.g., small pox) adds to the
devastation.3  Congress has attempted to diminish the panic among Americans by 
implementing the Project BioShield Act of 2004.4  This Act aims to disperse funds for the 
stockpiling of vaccines by streamlining FDA approval of new drugs/medical products.5

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1 Sidel, Victor, Biosword, BioShield , Gene Watch v.17, n.5/6 Sep-Dec 2004 1sep04 available at
http://www.mindfully.org/GE/2004/Biowarfare-Biosword-BioShield1sep04.htm.
2
 Steve Schultze and Meg Jones, Many Americans Fear Another Terror Attack, Poll Finds, JSOnline 
Milwaukee Journal Sentinel available at http://www.jsonline.com/news/gen/sep03/167391.asp.
3
 How Great a Threat? Interview with bioterrorism expert Jonathan B. Tucker, National Review Online 
(October 2001) available at http://www.nationalreview.com/interrogatory/interrogatory101501.shtml.
4
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004
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In a momentary glance, Project BioShield appears to be an effective and valuable 
response to the looming fear of a biological or chemical weapons attack.  However, when 
analyzing the Act with greater scrutiny, the negative points and unrealistic intentions are 
prominent.  For example, the expedited approval of drugs through the Food and Drug 
Administration (“FDA”), which empowers the FDA with unprecedented authority.
Moreover, legislators believe that Project BioShield is a frivolous unnecessary law.6  The 
Honorable Jeff Flake stated:
This legislation is another example of the federal government attempting 
to throw money at a project that is already underway.  The Department of 
Health and Human Services already administer the Strategic National 
Stockpile, which combat the public health consequences of a terrorist 
attack or public health emergencies.  The Department of Homeland 
Security currently provides the financing for those efforts … About $400 
million was appropriated in 2003 for stockpiling activities. 7
This comment will first explore the meaning, purpose, and objectives of Project 
BioShield.  Second, there will be an overview of how a normal medical product seeks 
approval under ordinary circumstances.  This will include an explanation of the three 
stages of testing implemented by Pharmaceutical companies, which are seeking FDA
approval to market new products.  Third, Project BioShield will be compared to the 
emergency approval section already included within the FDA code of regulations.  
Fourth, a discussion of bioethical dilemmas which may result from the streamlined
approval process allowed under Project BioShield will address concerns of informed 
consent and allocation of vaccinations, with emphasis on the first contract awarded under 
the act.  Finally, the paper will conclude by examining potential remedies available to 
individuals harmed from medication administered under Project BioShield. 
6
 150 Cong. Rec. E1399-01 (July 14, 2004).
7 Id.
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I.  PROJECT BIOSHIELD: AN OVERVIEW
On May 19, 2004, the United States Congress accepted the Project BioShield Act 
of 2004 with a colossal majority vote.89  In July 2004, President Bush signed the Act into 
law.10
The purpose of the Act is to create a “Strategic National Stockpile” of drugs, 
vaccines, and other products in such amounts as the Secretary of Health and Human 
Services (“the Secretary”) deems necessary and realistic in the event of biochemical 
terrorist attack.11  In order to ensure that necessary amounts of medical products are 
available for vaccines, the Secretary may award contracts or enter into agreements with 
appropriate companies.12  The contract may require a discounted price, require an 
availability of the vendor to store the vaccines/products, and the vendor to seek approval 
from the Secretary.13 Additionally, any contract entered into by the government is 
limited to eight years and can only be renewed for periods not exceeding five years.14
8
 Congress.Org, Capital Advantage, Project BioShield Act Passage of the Bill available at 
http://capwiz.com/congressorg/issues/votes/?votenum=99&chamber=S&congress=1082
9
 Timeline of Project BioShield: October 2001: “A Letter laced with anthrax was delivered to Capitol Hill, 
underscoring the nation's vulnerability to bioterrorism.-January 2003: In his State of the Union address, 
President Bush announced Project BioShield, an effort to make available new and innovative drugs and 
vaccines to better protect against biologic attack.- March 2003: Legislation to implement Project BioShield
was introduced in Congress- July 2003: The House of Representatives approved 421-2 a version of the 
legislation; however, consideration slowed in the Senate because of funding authorization and 
appropriations questions.-May 19, 2004: The Senate approved 99-0 its version of Project BioShield-July 
14, 2004: The House approved 414-2 the Senate-passed bill-July 21, 2004: The president signed Project 
BioShield into law.  Sidel, Victor, Biosword, BioShield , Gene Watch v.17, n.5/6 Sep-Dec 2004 1sep04 
available at http://www.mindfully.org/GE/2004/Biowarfare-Biosword-BioShield1sep04.htm.
10
 President signs Project BioShield Act of 2004, The White House President George W Bush, available at
http://www.whitehouse.gov/news/releases/2004/07/20040721-2.html
11
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 319F(a)(1)).
12
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 319F(b)(1)).
13
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 
319F(C)(ii)(I-VI).
14
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 
319F(C)(ii)(III).
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One major emphasis of Project BioShield is to permit the emergency approval of 
a medical product in the event that of an emergency declaration.15  A declaration of 
emergency is defined in three subsections:
(A) A determination by the Secretary of Homeland 
Security that there is a domestic emergency or a 
significant potential for a domestic emergency, 
involving a heightened risk of attack with a specified 
biological, chemical, radiological, or nuclear agent or 
agents;
(B) A determination by the Secretary of Defense that 
there is a military emergency, or a significant potential 
for a military emergency, involving a heightened risk to 
United States military forces of attack with a specified 
biological, chemical, radiological, or nuclear agent or 
agents; or
(C) A determination by the Secretary of a public health 
emergency under section 319 of the Public Health 
Service Act that affects, or has a significant potential to 
affect, national security, and that involves a specified 
biological, chemical, radiological, or nuclear agents or 
agents, or a specified disease of condition that may be 
attributable to such agents or agents.16
An emergency declaration can expire in two ways.17  The determination of expiration
may be made by the Secretary in collaboration with an appropriate government 
subsidiary or else the declaration will expire one year after the date the declaration was 
announced.18
Under Section 564 of the statute, Authorization for Medical Products for Use in 
Emergencies, the Secretary may authorize a “drug, device, or biological product intended 
15
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 564).
16
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 564 
(b)(1)(A)(B)(C) ).
17
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 564 
(b)(2)(A)(i)(ii) ).
18 Id.
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for use in an actual or potential emergency” into the medical arena.19  The emergency 
authorization allows for the introduction of a drug which has not been approved for 
distribution and/or a drug that has been approved, but not for the particular intended 
use.20
These criteria are ambiguous as to what constitutes an emergency worthy of 
approval, though Project BioShield does include a section veered toward the scope of 
authorization.  For an unapproved product, the health care professional administering, as 
well as the individual receiving the product, must be informed that the product has been 
authorized for an emergency use.21  To the extent possible, recipients are to be informed 
of all the known and potential benefits and risks.22 However, the Act does not require 
individual recipients of a given product to be informed that the product is generally 
“unapproved,” they are merely told it is approved by the Secretary for emergency use.23
Particulalry striking, Project BioShield bestows upon the FDA an expedited 
emergency authorization power which overrides the emergency approval process already 
enacted within the FDA.24 The reasoning for this expansion of the existing FDA 
emergency process,is to further streamline approval of medical products.  In order to 
illustrate the differences between the FDA and Project BioShield’s respective approval 
processes, it is necessary to understand how a new drug typically attains approval.  The 
section that follows will lay out the life and formation of a new drug created by a 
pharmaceutical company.  
19
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 564 (a)(1)m
20
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 564 
(a)(2)(A)(B)),
21
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 (Section 
564(e)(1)(A)(i)-(ii).
22 Id.
23 Id.
24
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004
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II. TYPICAL ROADMAP OF A DRUG/VACCINE’S QUEST FOR APPROVAL
At Alliance Pharmaceutical, a new drug, seeking non-emergency approval,
undergoes twelve years of testing before receiving FDA approval.25  This twelve-year 
process begins with an initial period consisting of preclinical testing, which examines the 
safety and biological activity of the new medicine.26 Preclinical Testing takes place over 
three and one half years.27  On average, 5000 compounds enter the preclinical testing 
stage, which is preceded by the filing of an Investigational New Drug (“IND”) 
application to the FDA.28  The FDA endorses an average of five out of the 5000 
compounds to advance into the next stage, which is compromised of three phases of 
human clinical testing. 29
After successfully completing the preclinical testing stage, Phase One begins.30
In Phase One testing, the new medical product is tested on twenty-eighty healthy 
volunteers.31  Phase One lasts one year.32  Once the new medicine completes Phase One, 
Phase Two, consisting of 100-300 patient colunteers, commences.33 34  These are the 
stereotypical type of patients who would be administered the medicine once FDA 
approval is received.35  Phase Two is conducted over a period of two years.36  Finally, the 
25
 Alliance Pharmaceutical Company, Phases of Product Development, available at
http://www.allp.com/drug_dev.htm. 
26 Id.
27 Id.
28 Id.
29 Id.
30 Id.
31 Id.
32 Id.
33 Id.
34 Id.
35 Id.
36 Id.
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last phase of human testing is Phase Three,37 comprised of 1000-3000 patient 
volunteers.38  This phase lasts for three years.39 Subsequent to the three phases of human 
analysis, an additional application (New Drug Application or “NDA”) is processed with
the FDA.  If the product survives the twelve-year testing process, one drug enters into the 
final two-year review and approval process from the FDA.40 However, additional post 
marketing testing by the pharmaceutical companies is also mandated after the two-year 
review is completed.41
The need for this twelve-year assurance process is clear:  The pharmaceutical 
company’s aim is to benefit individuals and avoid or diminish any potential harmful 
consequences.  Although safety is a principal concern, emergencies do occur and,
therefore, the FDA is obligated to allow for a quicker access/approval under certain 
circumstances for some medications.42 The following section reviews the differences 
between previously existing FDA regulations and the expansive approval procedures of 
Project BioShield.
III.   PROJECT BIOSHIELD ACT V. FDA
The FDA has implemented an emergency approval section to respond 
appropriately when a medical product needs to be available to the public, and, due to the 
emergency, more expedient testing and research procedures are required.  Thus, under 
extreme emergencies, medical products need not be subjected to the stringent, twelve 
37 Id.
38 Id.
39 Id.
40 Id.
41 Id.
42
  Food and Drug Administration , Department of Health and Human Services, Treatment use of an 
investigational new drug, 21CFR § 312.34.
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year testing before becoming available for public use.  Under section 312.34 of the FDA, 
a drug not approved for marketing is allowed, but only under clinical investigation.43
Moreover, the drug will only be approved under 312.34 for treatment of a life threatening 
condition where there are no other available alternatives.44
Therefore, according to 312.34, a drug may conceivably be accessible as early as 
Phase Three testing, but no earlier than Phase Two.45 As a result of early approval under 
312.34, a drug used for emergency treatment may be available in as little as 6.5-9.5 
years.46 A detailed comparison between 312.34 of the FDA and Project BioShield is 
illustrated in the following section.
Paragraph 564 of Project BioShield, entitled “Authorization for Medical Products 
for Use in Emergencies,”47 represents the Bush administration’s proposed solution to a 
possible life-threatening terrorist attack.  This provision grants the Secretary full 
discretion to deem a drug, or biological product available for use in an actual or potential 
emergency.48  This section further allows the authorization of a drug which is not 
approved or approved for an alternate diagnosis or remedy.49 However, this section 
seems ambiguous because of the absence of any guidelines of what steps, research or 
advances will be secured before administration to the general public is allowed. 
Project BioShield attempts to minimize this ambiguity under a section titled 
43 Id.
44 Id.
45 Id.
46 Id.
47
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 ( Section 564 (a) 
parts (1) and (2) ).
48 Id.
49 Id.
Jodi Anne Phillipo
Project BioShield Comment
9
“Criteria for Issuance of Authorization.”50  This section states that the Secretary’s 
authorization of a drug is not to be executed unilaterally, rather, it should be made in 
conjunction with the Director of the National Institutes of Heath and the Center for 
Disease Control and Prevention.51 The above parties must determine that the possible 
threat to the United States MAY cause serious life threatening conditions to the general 
public,  and the product to be distributed MAY be effective in diagnosing or treating the
condition.52 The group must also find that the  POSSIBLE benefits outweigh the risks, 
which will be determined by scientific studies if such are available and there are no 
alternatives to the drug at issue.53
 The Act is unclear as to what will be designated a life-threatening event or even 
what extent of certainty is necessary to issue a given product in the case of a possible life-
threatening attack. This is very puzzling given the steps the United States has taken in 
the last four years to designate the possibilities of another terrorist attack.  In the last four
years, the government has implemented a color scheme to show the likeliness of a 
terrorist attack, the color rises when there is a possibility of terrorism and the United 
States is on high alert.54  After numerous elevations on the scale, with no corresponding 
attempt taken by a terrorist on US soil, the US population is confused by the color code 
scheme.55  Therefore, it would appear that the Bush administration’s credibility of 
determining a possible life-threatening attack has been diminished.
50
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 ( Section 564 (c) ).
51 Id.
52 Id.
53 Id.
54
 Kelly Thornton, Ridge admits upgrade needed in color-coded alert system, The San-Diego Union 
Tribune (December 15, 2004) available at
http://www.signonsandiego.com/uniontrib/20041215/news_1n15ridge.html.
55 Id.
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In addition, the Project BioShield Act contains a section designated “Conditions 
of Authorization” as an attempt by the Bush administration to eliminate confusion.56  The 
Conditions of Authorization speak to the fact that when an unapproved product is 
administered, conditions are necessary to protect the public health.57 These conditions 
include an order that the health care professionals who are administering the drug and the 
individuals receiving the drug be informed that this product is authorized by the Secretary 
for emergency use.  The information presented must also make the providers and 
receivers aware of the known or unknown risks and benefits.58  Furthermore, the 
Secretary wants to implement a plan for the monitoring of the newly approved products.59
Project BioShield appears to be an attempt to further streamline a medical product 
through the FDA at a higher rate than the emergency approval criteria already enacted 
under the FDA.
The language of the FDA’s determination of an emergency approval is stated as
follows: “Emergency use is defined as the use of an investigational drug or biological 
product with a human subject in a life-threatening situation in which no standard 
acceptable treatment is available and in which there is not sufficient time to obtain IRB 
approval.”60  An emergency approval is termed under two phases, a life threatening 
disease or a serious debilitating illness.61  Although the FDA, like the Project BioShield
Act, does not seem to clarify what constitutes an emergency situation, the FDA has 
56
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 ( Section 564 (e) ).
57 Id.
58 Id.
59 Id.
60 US Food and Drug Administration, Guidance for Institutional Review Boards and Clinical Investigators
1998 Update available at http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html#emergency (last visited on 
October 2004).
61 Id.
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established different criteria to determine what constitutes an emergency.62  For example, 
if the product is designed to treat a life-threatening biological blood product, its 
emergency approval status is decided by the Office of Blood Research.  Similarly, if the 
product is delegated as a biological vaccine, its emergency status is reviewed by the 
Office of Vaccine Research.63
After researching section 312.34 of the FDA and comparing it to the Project 
BioShield Act, many questions remain unanswered:  Are these conditions enough to 
guard the United States population against the possible side effects of products which 
have not gone through vigorous FDA approval procedures?  Under the Project BioShield
Act are the risks and benefits known or adequately disclosed to the person receiving the 
medicine? Shouldn’t the mere fact that the drug was streamlined through the 
investigational stage by FDA authorization be sufficient to warrant a cautionary label
indicating the product’s status as an “Investigational Drug?”
IV. AMERICAN CITIZENS: UNWITTING HUMAN RESEARCH SUBJECTS 
UNDER PROJECT BIOSHIELD
Although under the Project BioShield Act, the Secretary intends to enforce 
“conditions” to monitor any adverse effect and symptomology related to the use of a
drug, the Act essentially treats the United States population as a mass of human test
subjects.64  Presently, the intent of the initial stages of human clinical testing of a non 
emergency product monitored by the pharmaceutical companies, is to limit dispensation 
62 Id.
63 Id.
64 See Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004.
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of a new drug to pre-screened individuals who are closely monitored.65 Under Project 
BioShield, the administration of a new drug to large numbers will not allow the detailed 
mechanisms necessary to adequately monitor the effectiveness and possible side effects 
of new products.  The government appears to be ignoring the possibility that tests 
conducted on animals and preliminary research does not correlate the same results when 
the drug is ingested by humans. The requirements implemented to monitor adverse 
effects of new drugs approved under Project BioShield may be ineffective in eliminating 
unknown risks due to the government’s inability to monitor mass amounts of people who 
may be administered a streamlined drug.  In short, Project BioShield does not meet the 
requirements necessary for informed consent for the following three reasons;  individuals 
administered with the medical product can not effectively be monitored; the exact terms 
of the emergency authorization are not disclosed; and the risks and benefits are to 
speculative to gather adequate informed consent.
A. Informed Consent and the need for Close Monitoring of Human Subjects
In a recent case, Lenahan v University of Chicago, 808 NE 2d 1078, a patient 
participating in a cancer trial was not taken off the medication at the first adverse sign 
and died as a result.  Her estate filed suit against the University of Chicago and a 
judgment was awarded in the estate’s favor.  The court’s decision was based in part on 
the fact that the human subject was not followed with the closeness that is required
during an investigational human trial.66 This case stands for the proposition that the use 
of unapproved drugs, where the risks are unperceived, is dangerous to the general public.  
For this reason, continuous monitoring is mandated for human subjects. Lenahan, in 
65 See Alliance Pharmaceutical Company, Phases of Product Development, available at
http://www.allp.com/drug_dev.htm.
66 Lenahan v. University of Chicago, 808 N.E.2d 1078.
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which the court found that the human subject was not followed closely enough to prevent 
her death, illustrates that, although the Act appears to have the genuine intent to monitor 
the actual number of persons administered a streamlined product, such a task may simply 
not be feasible.67
B. Informed Consent and Failure to Correctly Term the Product an
Investigational Drug
Furthermore, using the term “emergency authorization,” as opposed to disclosing 
that the drug is investigational, does not compensate for investigational shortcomings and 
fails to adequately inform consumers about the product.  This non-disclosure creates a 
problem with general requirements of informed consent.  The underlying purpose of 
informed consent is to give a patient autonomy and choice regarding their health care 
decisions.68 Informed consent necessitates that patients be adequately informed of the
risks and benefits of a particular study or treatment before agreeing to participate or have 
the treatment administered.69 Disclosure of the risks  and benefits of a given product or 
treatment is indispensable because if a patient is not aware of these risks, then the patient 
can argue that they were not given the necessary information to make an informed 
decision.70
In the case of Daum v. Spine Medical Group Inc. et. al., the California Court of 
Appeals declared that when a medical product is investigational or experimental, the 
patient must be informed of the product’s status and written informed consent must be 
67 Id.
68 Frans C.B. van Wijmen and Frank W.S.M. Verheggen, MYTH AND REALITY OF INFORMED CONSENT IN 
CLINICAL TRIALS, 16 MEDLAW 53, 1997.
69
 The Rebirth of Informed Consent: A Cultural Analysis of the Informed Consent Doctrine after Schreiber 
v. Physicians Insurance Co. of Wisconsin, Northwestern University Law Review, 95 NWULR 1029, 
Spring 2001. 
70 See Id.
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provided for the patient.71 This case further supports the contention that, although, 
Project BioShield makes authorization contingent on notification that the product has 
been approved for emergency use, this does not compensate for the lax approval process 
and failure to fully disclose the drug’s investigational status.72
Individuals may have knowledge of the product’s emergency authorization and 
any known risks and benefits, but they are not being informed of the product’s inherent 
experimental nature.73 A recent article explains this dilemma:
With experimental procedures . . . the risks are unknown. Therefore, if a 
patient has consented to a particular medical intervention and has not been 
made aware of the experimental nature of the treatment, the intervention 
may be considered a ‘substantial variance’ from the treatment for which 
consent had been given.74
Under the FDA’s own guidelines, informed consent must be acquired before 
administering an investigational drug unless receiving this consent is not feasible.75 This 
problem may only be an issue pertaining to the Project BioShield because under section 
312.4, the FDA protects itself from issues arising because of informed consent:
A critical responsibility of the investigator and the IRB has always 
included ensuring that there is an adequate informed consent process for 
study subjects. When preclinical teratology and reproductive toxicology 
studies are not completed prior to the initial studies in humans, male and 
female study subjects should be informed about lack of full 
characterization of the test article and the potential effects of the test agent 
on conception and fetal development. Al study subjects should be 
provided with new pertinent information arising from preclinical studies 
as it becomes available, and informed consent documents should be 
updated when appropriate.  Study subjects should also be informed about 
71
 Daum v. Spine Medical Group Inc. et at., 52 Cal.App.4th 1285 at 1293.
72
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004 ( Section 564 (e) ).
73
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004
74
 Involuntary Cloning, A Battery Notes 130-134.
75
 21 CFR 505(i)
Jodi Anne Phillipo
Project BioShield Comment
15
any new clinical data that emerge regarding general safety and 
effectiveness, including relevant gender effects.76
As previously noted, Project BioShield only requires that individuals be informed that 
the drug has been approved for emergency use.77  A requirement of informing individuals 
that the product has not been tested on humans or has been streamlined through the 
approval process, as seen under the FDA, would help to eliminate the problems regarding 
informed consent that arise from the Act’s deficient information disclosure policy.  
The terming of a product as ‘available for emergency use’ does not lead a prudent 
person to believe that they may be receiving a product which has not formerly been 
approved by the FDA and has not undergone human clinical testing. Thus, comparing a 
person being treated with this medication to a human test subject is not such a farfetched
analogy.  It warrants noting that the government consciously wrote language into the Act 
which requires that participating patients are monitored and any adverse symptoms
recorded.78  However, this language includes no guidelines and the ability to monitor a 
mass amount of people is highly impracticable at best and at worst nearly impossible.79
C. Informed Consent and Unknown Risks and Benefits
Problems with informed consent are also encountered when the risks and benefits
of a particular treatment are unknown.80  To achieve valid informed consent there needs
to be a process whereby the outcomes of the treatment and reactions of treated persons 
are communicated to the potential user.  Further, an outline of the known or potential 
perils of taking the product must be available.
76 US Food and Drug Administration, Guidance for Institutional Review Boards and Clinical Investigators
1998 Update available at http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html#emergency (last visited on 
October 2004).
77
 Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004
78 Id.
79 See Project BioShield Act of 2004, 108th CONGRESS, 2d Session S. 15, July 16, 2004
80
 Daum, 52 Cal.App.4th at 1293.
Jodi Anne Phillipo
Project BioShield Comment
16
The decision in Pinnick v. Louisiana State University Medical Center stands for 
the proposition that, according to the doctrine of informed consent, a health care provider 
has a duty to disclose to the patient the known risks, unknown risks, alternatives to the 
medication, and risks involved if medication is not taking.81
In the midst of an emergency situation, Project BioShield obligates health care 
personnel to acquaint an individual obtaining a vaccine or medication with the potential 
risks and benefits.82  The individual will not know that the risks and benefits disclosed to 
him or her are barely speculative.  In some cases, human clinical trials were not 
completed in a manner to even actualize a rationale for producing possible risks.  
Therefore, the individual is not consenting to the risks; rather, he or she is only giving 
consent for the administering of a medication which they believe has achieved FDA 
emergency approval. A prudent layperson would associate the FDA approval as one that 
occurred after animal and clinical human trials.  Consequently, since the FDA does not 
know the risks, it is inconceivable that the government sustain that, under these 
circumstances, an individual can adequately formulate a voluntary and knowing consent. 
It is unprecedented, and more than arguably unethical, that any unapproved drug, which 
has not been tested in clinical trials, can meet the elements of informed consent. Even
more suspicious is the fact that the government has contoured the regulations set forth 
within the Act itself, which states emergency authorization grants the administration of 
medication where the benefits outweigh the risk to circumvent the legal definition of 
informed consent.83
81 Pinnick v Louisianna State University Medical Center, 707 So.2d 1050 (La.App. 2 Cir.,1998). 
82 Id.
83 Id.
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In order to escape liability for informed consent, the government and product 
manufacturers should impose a consent form stating the drug is experimental and the 
risks and benefits are unknown and have not been identified through customary 
emergency testing procedures enforced by the FDA upon Pharmaceutical companies.84
VI. FIRST CONTRACT AWARDED UNDER PROJECT BIOSHIELD ACT
On November 4, 2004, the first contract award under Project BioShield
was issued.85  The contract was awarded to VaxGen, Inc., a biotechnology company 
located in Brisbane, California.86 The contract is for five years and pertains to a 
vaccination for the Anthrax virus.87  VaxGen, Inc. has agreed to provide enough 
vaccinations to treat approximately twenty-five million people and anticipates the vaccine 
will be ready for delivery sometime in 2006.88  The government plans to put these doses 
aside for use in the event of an anthrax attack.89 The contract expressly states that 
payment for the vaccine will not be received until VaxGen makes delivery to the 
government for stockpiling.90  In regards to the payment terms, the president of VaxGen 
stated: “The company is putting a lot of risk to be involved in this . . . .  It’s going to 
make America a lot safer.”91
However, the company must still meet some additional requirements before it 
can execute the government contract.  Specifically, Project BioShield requires that a 
84
 Davis v. Hoffman, 972 F.Supp. 308(E.D.Pa 1997). 
85
 Diedtra Henderson, U.S. to Buy New Generation Anthrax Vaccine, available at
http://aolsvc.news.aol.com/news/article.adp?id=20041104171109990005&_mpc=news%2e10%2e15&cid=
474 (last visited November 2004).
86 Id.
87 Id.
88 Id.
89 Id.
90 Id.
91 Id.
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vendor such as VaxGen seek licensing, approval or clearance from the Secretary prior to 
making delivery to the National Stockpile.92  However, at this point in time VaxGen has 
not successfully obtained licensing from the FDA.93
After animal research and clinical trials on 580 people, the anthrax vaccine 
developed by VaxGen has been contemplated to be effective in all humans.94 Interesting 
to note, the VaxGen product is not a completely new product.  Other manufacturers, such 
as BioPort Corporation, have developed anthrax vaccines similar to VaxGen’s.95 One 
existing vaccine is manufactured by BioPort Corporation.  Bioport is currently under an
877.5 million dollar contract with the Pentagon negotiated before the development of 
Project BioShield.96 HHS has decided to include a minimum of five million doses of
Bioport’s anthrax vaccine in the national stockpile.97 Many critics of the Act hope to see 
more of this type of diversification of vaccine providers.98
We share Secretary Thompson's stated objective of securing a 
sufficient stockpile of safe and effective vaccines to protect the 
American public against a future bioterrorist attack . . . . We 
believe the most meaningful way to achieve that important goal is 
for the national stockpile to include products from multiple 
92 Id.
93
 Diedtra Henderson, U.S. to Buy New Generation Anthrax Vaccine, available at:
http://aolsvc.news.aol.com/news/article.adp?id=20041104171109990005&_mpc=news%2e10%2e15&cid=
474 (last visited November 2004).
94 Id.
95 Id.  “BioPort’s AVA vaccine requires six doses and is dervived from cell cultures.  The newer generation 
anthrax vaccine that VaxGen is making is known as a recombinant protective antigen (rPA0 protein and is 
designed to improve immunity with three doses.” BioTech Watch, Bioterrorism Senators Alter Drug Patent 
Incentive in ‘BioShield II’ to Address Concerns, ISSN 1535-5284 (December 17, 2004) available at:
http://pubs.bna.com/ip/BNA/btb.nsf/is/A0B0E0R9H5.  
96
 Diedtra Henderson, U.S. to Buy New Generation Anthrax Vaccine, available at:
http://aolsvc.news.aol.com/news/article.adp?id=20041104171109990005&_mpc=news%2e10%2e15&cid=
474 (last visited November 2004); See also BioTech Watch, Bioterrorism Senators Alter Drug Patent 
Incentive in ‘BioShield II’ to Address Concerns, ISSN 1535-5284 (December 17, 2004) available at:
http://pubs.bna.com/ip/BNA/btb.nsf/is/A0B0E0R9H5.  
97 Id.
98
 BioTech Watch, Bioterrorism Senators Alter Drug Patent Incentive in ‘BioShield II’ to Address 
Concerns, ISSN 1535-5284 (December 17, 2004) available at:
http://pubs.bna.com/ip/BNA/btb.nsf/is/A0B0E0R9H5.  
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suppliers, due to performance risks associated with any single 
product or single manufacturer.99
Due to the fact that there have already been anthrax vaccines developed, the first 
contract awarded under Project BioShield has a diminished risk because there is more 
time and resources available to the corporation for clinical trials.  However, although this
contract should be considered much safer compared to other vaccines which may be 
streamlined through the FDA without such time and resources, this vaccine’s safety is 
still questioned.100  Moreover, although the FDA feels this vaccination is safe, the exact 
effect of the vaccine is still uncertain and, therefore, it is not prudent of the United States
to buy so much of the vaccination, which is still in its experimental stage.101
An original anthrax vaccination administered to U.S. soldiers has heated much 
debate. The initial distribution of the vaccine was to troops deployed to Iraq for more 
than fifteen days.102  The vaccine caused many health problems, from severe headaches 
to death.103 Due to the serious health issues associated with the drug, many military 
personnel have since refused to be vaccinnated.104 Apart from the side effects, another 
concern is that the drug is still experimental in nature because it had only completed 
phase one testing.105  This is precisely the type of scenario that shows the dangers of 
forgoing the final phases of clinical testing.  
99 Id.
100
 Justin Gillis, U.S. to buy Anthrax Vaccine, Stockpile Would Permit Mass Inoculations, Washington Post
(March 12, 2004) available at: http://www.washingtonpost.com/ac2/wp-dyn/A51691-
2004Mar11?language=printer.
101 Id.
102
 Meryl Nass, Is the Anthrax Vaccine Really Safe? What You Must Know About "Project BioShield", 
Washington Post (March 27, 2004) available at
http://www.mercola.com/2004/may/8/anthrax_vaccine.htm.
103 Id.  This vaccination has also been cited to have caused severe autoimmune deficiencies and 
neurological disorders.  An army surgeon has discussed these problems and has consulted with a vaccine 
expert for a second opinion.  Id.
104 Id.
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Returning to the VaxGen product, it has been commented that the vaccine is an
improvement on the existing products, however, its acceptance within the medical 
community has met with much hesitation and speculation.106 Many critics emphasize 
that the public should not be so quick to assume that improvements upon the existing 
models will result in a product with no adverse risks.107
Also interesting to note, is that an anthrax biochemical attack has been a concern 
for a number of years.108  The Clinton administration, in 1998, announced plans to 
stockpile Anthrax vaccines after the President was informed that the United States was 
vulnerable to a biological attack.109  If all the contracts to be awarded pertained to a 
bacterium that the United States has had notice of for over six years and which has more 
than one manufacturer, such as in this scenario, then Project BioShield would not be as 
risky and the emergency approval section would not be crucial.  Notwithstanding the fact 
that the anthrax bacterium has been around for years, there are still serious concerns.
VaxGen rests the safety of its vaccine on humans based on a trial of only 580 
human subjects.110 Under normal testing procedures of a new medical product, human
testing lasts for approximately six years and constitutes between 1200 and 3200 human 
subjects.  This is more than double the human subjects which have been tested by
VaxGen.  Clearly, because this bio-terror threat has been known for so long a time, more 
106 Paula Zahn Now, CNN Security Watch: Anthrax; McCain: No Confidence in Rumsfeld; Interview With 
Rusty Yates, December 14, 2004 available at: http://www.thepowerhour.com/news/zahn_anthrax.htm. ); 
See also Peter Gorner, U.S. war on anthrax has its risk, Rush to stock new vaccine has scientists wary,
Tribune Science (march 28, 2004) available at  http://www.anthraxvaccine.org/tribune_article.html.  This 
article emphasis’s that “Although the vaccine has been tested in animals, testing in humans is in its early 
phases and the vaccine has not yet demonstrated its effectiveness, making the purchasing plan premature, 
according to critics.” Id.
107 Id.
108 BBC News, Clinton warns against ‘cyber attacks,’ available at
http://news.bbc.co.uk/1/hi/world/americas/98983.stm (last visited November 2004).
109 Id.
110 Jonathan D. Moreno, BIOETHICS AND THE NATIONAL SECURITY STATE, 32 JLMEDETH 198, 
summer 2004.
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human subjects could have and should have undergone testing.111 Taking this into 
consideration, the proposition that other products created pursuant to the Act to combat 
new forms of bio-weapons with which the government has had little to no experience 
could be safe and effective without undergoing full clinical testing and research, seems a 
hazardous assumption.
Finally, stockpiling only consists of twenty-five to thirty million vaccines 
stockpiled.112  The United States has an approximate human population of 294,699,968, 
with this number growing each day.113 Therefore, there is greater than ten times more 
people in the United States then there is anticipated to be of vaccines in the National 
Stockpile.  This can lead to a Bioethical issue analogous to the shortage of the flu vaccine 
in the United States today.114
V. CONCERNS TO WATCH FOR IN PROJECT BIOSHIELD’S FIRST CONTRACT
During the flu season of 2004-2005,there was not enough of the flu vaccine to go 
around.115  Although this is not the first time the United States has had a flu vaccine 
shortage, the constraint was exacerbated due to 48 million doses which were expected to 
be available but were contaminated.116 “These shortages have forced physicians and 
public- health officials to wrestle with who should, and who won’t, get the vaccine.”117
Although, the government may mandate that only individuals in the high risk category 
111
 Alliance Pharmaceutical Company, Phases of Product Development, available at
http://www.allp.com/drug_dev.htm.
112 Supra note 76.
113
 U.S. Census Bureau, U.S. POPClock Projection available at  http;//www.census.gov/cgi-bin/popclock 
(Last visited November 2004).
114
 Breaking Bioethics, Flu Shortage poses public health disaster, federal and state governments should 
declare emergency, available at http://www.msnbc.msn.com/id/6291712/ (Last visited November 2004).
115 Id.
116 Id.
117
 Flu Shot ethics, available at http://ibb7.ibb.gov/newswire/377b85f5.html (last visited November 2004).
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may receive the vaccine, this doesn’t eliminate the possibility of a public disaster.118  For 
example, greedy consumers are bribing hospitals to allow them access to the flu shot for 
eight times the normal price, doctors are administering the flu shot to friends and family 
members who are not in the high risk category, and in Colorado and Pennsylvania, people 
have stolen the flu shot from stores.119
In the United States, around five to twenty percent of the population become
infected with the flu each year.120  Of this percentage range, each year 36,000 will die.121
Thus, a low percentage of the infected population runs the risk of having a deadly 
reaction to the flu.  Anthrax is a much more serious disease.  Twenty percent of people 
who contract Anthrax will die from complications of the disease.122 If people are going 
through such measures, i.e. stealing the vaccine from stores when dealing with the 
common flu, then what can be expected in the face of a shortage of a vaccine,for a 
disease, like Anthrax, that one in five people may die from.123  Although the flu is more 
contagious, a terrorist may be able to develop the Anthrax bacterium in such huge 
amounts as to affect a mass amount of Americans.124 Therefore, if there is an Anthrax 
threat where more than twenty-five million have the possibility of being infected, then 
this shortage of vaccinations may cause the same type of public crisis being seen in 
118
 Breaking Bioethics, Flu Shortage poses public health disaster, federal and state governments should 
declare emergency, available at http://www.msnbc.msn.com/id/6291712/ (Last visited November 2004).
119 Id.
120
 Centers for Disease Control and Prevention, Influenza: The Disease, available at
http://www.cdc.gov/flu/about/disease.htm (lat visited November 2004).
121 Id.
122
 University of Maryland Medicine, Anthrax: What You Should Know, available at
http://www.umm.edu/features/anthrax.htm (last visited November 2004).
123 Id.
124 See id.
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today’s society in regards to flu.125 This is to say nothing of the much more difficult 
questions regarding who will decide which persons receive a dose, and on what basis 
these preferences may be made. This has the possibility of turning into a bioethical 
dilemma as seen in human organ allocation.126
Health and Human Services set forth new regulations on human organ allocation 
in 1999.127 Before these new regulations, the United Network for Organ Sharing
(UNOS) had the benefit of deference to its own policies.128  Now, UNOS must follow 
more strict and formal regulations, and any departure from the regimen regulations must 
be approved by HHS.129  One of the most significant alterations under the new policy is 
that organs are no longer to be donated with preference going a local contender, rather, 
the organs are to be allocated nationally.130  A contender must wait on the list until an 
organ becomes available, but due to the mass amounts of individuals waiting for each 
organ, potential recipients are to be identified based on both medical and non medical 
criteria.131  Examples of criteria used for organ allocation are “life expectancy, organ 
failure caused by behavior, compliance/adherence, repeat transplantation, and alternative 
therapies. ”132
125
 Breaking Bioethics, Flu Shortage poses public health disaster, federal and state governments should 
declare emergency, available at http://www.msnbc.msn.com/id/6291712/ (Last visited November 2004).
126
 Barry R. Furrow et. al, Bioethics: Health Care Law and Ethics 4th ed., West Group Publishing, 2001 
pages 394-409.
127 Id. at 392-93.
128 Id. at 393.
129 Id.
130 Id.
131 Id. at 395.
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Health and Human Services’ new regulation helps to eliminate a lot of problems 
arising amongst organ allocation, but seven states have enacted laws restricting out of 
state organ transfers, thus, difficulties are still noticeable in the organ transplant arena.133
This area of law has been extremely controversial and volatile throughout 
the past decade. Because the shortage of organs leads to some individuals 
not receiving needed transplants, many battles occur over what the proper 
allocating policies should be.  As a result, litigation in this area is constant 
and public outcry is often overwhelming.134
By limiting the number of vaccines stockpiled, the Secretary of Homeland Security is, in 
essence, paving the pathway to the same quandary seen in organ allocation except that 
the primary difficulties in organ allocation is caused by limited available organs, whereas
the problems of limited vaccinations are caused by poor planning.
As noted earlier the VaxGen contract and Bioport contributions to the stockpile 
leave enough vaccinations for only ten percent of potential U.S. recipients.135  Project 
BioShield provides that the Secretary
“shall maintain a stockpile or stockpiles of drugs, vaccines and other 
biological products, medical devices, and other supplies in such numbers, 
types, and amounts as are determined by the Secretary to be appropriate 
and practicable, taking into account other available sources, to provide for 
the emergency health security of the United States, including the 
emergency health security of children and other vulnerable populations, in 
the event of a bioterrorist attack or other public health emergency.”136
How the government determines the vulnerable ten percent earmarked to receive the
vaccination is ambiguous, leaving many questions and concerns unanswered. 
133 Id. at 397.
134 Id. at 393.
135
 Diedtra Henderson, U.S. to Buy New Generation Anthrax Vaccine, available at
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474 (last visited November 2004).
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The government asserts that the stockpile of vaccination is enough for an entire 
city affected with the anthrax virus.137  For example, the government plans to have 
enough vaccination for the population of New York City and Washington DC areas, but 
what if an Anthrax attack covers a wider area? Who wil get the vaccination then?138
VI. PROJECT BIOSHIELD PART II
From the Act’s beginnings, it was criticized by Senators such as hon. Jeff Flake, 
who stated that “BioShield would allow a company to spend several million dollars of its 
own money developing a new drug or vaccine, only to see the government possibly 
award the contract for producing it to another company.”139 This early criticism has 
become a reality.  Legislators are realizing that pharmaceutical companies are not 
pushing for contracts under Project BioShield.140 As a result, legislators ha ve drafted 
“BioShield II” to further incentivize pharmaceutical companies.141
BioShield II is known as the ‘wild card provision” and was presented to 
legislation as bill S. 666.142  The goal of BioShield II is to help induce pharmaceutical 
companies to do research and produce countermeasure drugs by offering two extra years 
of patent protection for the drug.143  However, the two extra years of protection is not 
mandatory, rather it’s the maximum amount of patent protection that the HHS Secretary 
137
 Justin Gillis, U.S. to buy Anthrax Vaccine, Stockpile Would Permit Mass Inoculations, Washington Post 
(March 12, 2004) available at http://www.washingtonpost.com/ac2/wp-dyn/A51691-
2004Mar11?language=printer.
138 Id.
139
 150 Cong. Rec. E1399-01 (July 14, 2004).
140
 BioTech Watch, Bioterrorism Senators Alter Drug Patent Incentive in ‘BioShield II’ to Address 
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may possibly award to a pharmaceutical company.144  Although this bill is in the 
embryonic stages, Sen. Orrin G. Hatch (R-Utah) criticized the language of the bill stating 
that, in essence, the bill allows patent protection “ no matter how unrelated [the drug 
produced is] to addressing bioterrorism and related threats.”145 Project BioShield only 
became a bill in July 2004, therefore measures to entice pharmaceutical companies to 
research and produce countermeasure drugs may be premature and unnecessary at this 
stage of the game.
VII. LIABILITY OF THE UNITED STATES UNDER PROJECT BIOSHIELD 2004
Now that potential issues/liabilities of the Project BioShield have been set forth, 
what are the remedies for those injured?  Project BioShield is a law imposed by 
legislation and because the United States has sovereign immunity in most cases, one 
possible way of holding the United States as a defendant is through the Federal Torts 
Claim Act.146  The Federal Torts Claim Act allows the United States to be liable in tort,
for instances such as personal injury and negligence, in the same manner a private 
individual would be liable to a plaintiff.147  The substantive law by which the action is 
decided upon is ruled by the state in which the action took place.148  The Federal Torts 
Claim act allows the United States to step in as a defendant when an employee of the 
government is being charged with numerous claims such as personal injury, medical 
144 Id.
145 Id.
146
 Federal Torts Claim Act, The 'Lectric Law Library's Legal Lexicon available at
http://www.lectlaw.com/def/f071.htm (last visited January 2005).
147
 27 U.S.C. § 2674; provided in relevant part Section 2 of Pub.L. 100-694 states:
”For more than 40 years the Federal Tort Claims Act 28 U.S.C.A. §§ 1346(b), 2671 et seq. has been the 
legal mechanism for compensating persons injured by negligent or wrongful acts of Federal employees 
committed within the scope of their employment.” Sec. 2 Pub.L. 10-694.
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malpractice etc.149  In an action under the Federal Torts Claim Act, the plaintiff may only 
seek an award of monetary value.150
In Goodman v. United States, Goodman sued the United States under the Federal 
Torts Claim Act.151  This action commenced when the husband of a diseased patient 
sought judgment for lack of informed consent on the part of his diseased wives 
physician.152 His wife died from a reaction to medication administered during clinical 
research for an experimental treatment for liver cancer.153  Although, Goodman was 
unsuccessful on his claim, the 9th Circuit Court of Appeals held that this type of claim, 
which alleged medical malpractice for failure to obtain patient’s informed consent, was 
broad enough to bring against the United States under the Federal Torts Claim Act.154
However, this was against one physician employed by the United States.155  The tricky 
part will be to construe a claim against a law enacted by the United States.  It may be 
possible to hold the contractor who developed the vaccine liable under the Federal Torts 
Claim Act, asserting he/she is an employee of the United States. In Letnes v. United 
States, the Court held that the “Government may be sued for actions of government 
contractor and its employees if Government has authority to control detailed physical 
performance of contractor and supervise its day-to-day operations.156”  Therefore, a 
person injured by an experimentally issued vaccination under Project BioShield may 
creatively bring forth a claim suing the company that developed the vaccination as a 
contractor alleging that the government had the authority to supervise the physical 
149 Id.
150 Id.
151
 Goodman v. United States, 298 F.3d 1048 (9 th Cir. 2002).
152 Id.
153 Id.
154 Id.
155 Id.
156 Letnes v. U.S., 820 F.2d 1517, 1519 (9th Cir. 1987).
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performance of the contractor by the stages and influences detailed within Project 
BioShield.   
VIII. CONCLUSION
September 11, 2001 changed the life of Americans in many ways and fears of 
another attack in the near future linger in American minds.157  The government has 
sought to eliminate some of this fear by introducing the Project BioShield Act.  In July 
2004, Project Bioshied became a law with George W. Bush’s signature of approval.158
One major emphasis of Project BioShield is to permit the emergency approval of a 
countermeasure drug in a declaration of an emergency.159 Under ordinary situations, a 
new medical product seeking approval is tested through three phases of clinical testing.160
These phases are easily distinguishable in a chart,161 such as the one below, shown in 
relevant part and produced by Alliance Pharmaceutical company;
Preclinical 
Testing Phase I Phase II Phase III FDA
Years 3.5 1 2 3 2.5
Test
Population
Laboratory and 
animal studies
20 to 80 
healthy 
volunteers
100 to 300 
patient 
volunteers
1000 to 3000
patient 
volunteers
Purpose
Assess safety 
and biological 
activity
Determine 
safety and 
dosage
Evaluate 
effectiveness, 
look for side 
effects
Verify 
effectiveness
and adverse 
effects
Review 
process  
Approval
Success 5,000 evaluated 5 enter trials 1 approved
157
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158
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However, when emergency approval is needed, a more efficient mechanism of 
approval is needed.  This is what the FDA emergency authorization and Project 
BioShield have sought to answer.  Section 312.34 of the FDA seeks expedited approval 
for a drug needed to aid in a life threatening condition where there are no alternatives 
available.162  Under the FDA, emergency approval can be sought before Phase Three of 
clinical testing.163  However, under Project BioShield, clinical testing may never be 
required or if it is on a level of much lower standards as the FDA’s emergency approval 
section.164  Project BioShield’s main aim is to have vaccines stockpiled in case of a 
biochemical terrorist attack, where FDA section 312.34 seeks approval for individual  life 
threatening illness.165  Conversely, even if approval is needed, clinical testing should 
never be overlooked.
Clinical testing isn't the only way to discover what effects 
drugs have on people. Unplanned but alert observation and 
careful scrutiny of experience can often suggest drug effects and 
lead to more formal study. But such observations are usually not 
reliable enough to serve as the basis for important, scientifically 
valid conclusions. Controlled clinical trials, in which results 
observed in patients getting the drug are compared to the results 
in similar patients receiving a different treatment, are the best 
way science has come up with to determine what a new drug 
really does. That's why controlled clinical trials are the only legal 
basis for FDA to conclude that a new drug has shown 
"substantial evidence of effectiveness."
It's important to test drugs in the kind of people they're meant to 
help. It's also important to design clinical studies that ask, and 
162
 Food and Drug Administration , Department of Health and Human Services, Treatment use of an 
investigational new drug, 21CFR § 312.34.
163 Id.
164
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answer, the right questions about investigational drugs. And 
that's no easy task. 166
Due to the importance of clinical testing, approval under Project BioShield is 
limited.  Therefore, it is argued that anyone receiving a vaccine which has gained 
expedited approval under Project BioShield should be warned of the drugs experimental
status and if not there is a lack of informed consent.167  However, informed consent is not 
the only bioethical problem under this law.  Under the first awarded contract, there is 
only enough vaccines stockpiled for ten percent of the population.  In essence, poor 
planning is paving the way to the same dilemma as organ allocation, unfortunately organ 
allocation is unavoidable, stockpiling vaccines is not.  After so much discussion, the 
unanswered question presented; Is Project BioShield a realistic resolution?  Due to 
problems such as informed consent and allocation it seems as though it may not be, but 
under a more advanced analysis it may be even more unrealistic.  Vaccinations such as 
small pox168 and anthrax have already been developed, but what if the terrorist 
organization where to introduce a new biochemical strain, would the United States be 
able to produce a vaccination for a new agent we aren’t prepared for?
 National Scientists do not believe so: 
“Senior scientists emphasize that they don't really know a 
straightforward way to create vaccines or antimicrobials, so they 
can't expect to find out soon. "We do not know the path for 
developing effective antimicrobial agents," Falkow says. "We just 
don't know what the right path is." … Furthermore, scientists have 
not discovered a new family of antimicrobials in 30 years. "It's not 
166 Flieger, Ken, Testing Drugs in People, FDA Consumer Special Report, January 1995 available at
http://www.fda.gov/fdac/special/newdrug/testing.html
167 Supra
168 US pledges smallpox vaccine for world stockpile, CDRAP (December 10, 2004) available at
http://www.cidrap.umn.edu/cidrap/content/bt/smallpox/news/dec1004stockpile.html.
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for lack of trying on the part of the pharmaceutical industry," Falkow 
says.169
Scientists fear that the United States does not have the ability to make an effective 
vaccine, but what about the vaccines already stockpiled under Project BioShield, are they 
effective?  After the complications that arose from the first vaccine administered to the 
troops, it can be surmised that the ‘new and improved’ vaccine may elicit unexpected 
health problems.170
For all the foregoing reasons, it is concluded that Project BioShield seems to be 
an realistic premature answer to the going threat of Biological or Chemical attacks.  The 
Hon. Flake agrees that Project BioShield is not a realistic solution.171
This legislation signifies an expenditure of extraordinary proportions that 
may be little more than a public relations campaign designed to reassure 
U.S. citizens that the government cares about bioterrorism.  I worry about 
the programs effectiveness when it is so blatantly ignores the way the 
market works, and I am not comfortable supporting such an expensive bill 
when too many questions have gone unanswered.172
169
 John Miller, Bioterrorism Research: New Money, New Anxieties, The Scientist (April 2003) available at
http://thescientist.com/yr2003/apr/profl_030407.html.
170 Supra at notes, 102-105.
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 150 Cong. Rec. E1399-01 (July 14, 2004).
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